Monocyte-derived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus.

Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc Natl Acad Sci U S A (2005) 2.34

Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol (2009) 1.92

Is HCMV a tumor promoter? Virus Res (2010) 1.81

Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol (2007) 1.68

Human cytomegalovirus-encoded interleukin-10 homolog inhibits maturation of dendritic cells and alters their functionality. J Virol (2004) 1.60

Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. J Clin Invest (2010) 1.50

Susceptibility of immature and mature Langerhans cell-type dendritic cells to infection and immunomodulation by human cytomegalovirus. J Virol (2003) 1.44

Comparisons of CD8+ T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness. J Virol (2009) 1.19

Cytomegalovirus-induced immunopathology and its clinical consequences. Herpesviridae (2011) 1.19

Human cytomegalovirus chemokine receptor gene US28 is transcribed in latently infected THP-1 monocytes. J Virol (2001) 1.18

Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus. J Virol (2006) 1.16

Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation. J Virol (2002) 1.15

Varicella-zoster virus infection of human dendritic cells and transmission to T cells: implications for virus dissemination in the host. J Virol (2001) 1.15

Human cytomegalovirus entry into dendritic cells occurs via a macropinocytosis-like pathway in a pH-independent and cholesterol-dependent manner. PLoS One (2012) 1.14

Identification of a mouse cytomegalovirus gene selectively targeting CD86 expression on antigen-presenting cells. J Virol (2004) 1.11

Inhibition of inflammatory interleukin-6 activity via extracellular signal-regulated kinase-mitogen-activated protein kinase signaling antagonizes human cytomegalovirus reactivation from dendritic cells. J Virol (2011) 1.08

Human cytomegalovirus gene products US2 and US11 differ in their ability to attack major histocompatibility class I heavy chains in dendritic cells. J Virol (2002) 1.08

Incoming human cytomegalovirus pp65 (UL83) contained in apoptotic infected fibroblasts is cross-presented to CD8(+) T cells by dendritic cells. J Virol (2000) 1.04

Human cytomegalovirus suppresses type I interferon secretion by plasmacytoid dendritic cells through its interleukin 10 homolog. Virology (2009) 1.04

Diagnosis and treatment of ulcerative colitis with cytomegalovirus infection: importance of controlling mucosal inflammation to prevent cytomegalovirus reactivation. Intest Res (2014) 1.03

Inhibition of CD1 antigen presentation by human cytomegalovirus. J Virol (2008) 1.02

Human cytomegalovirus inhibits differentiation of monocytes into dendritic cells with the consequence of depressed immunological functions. J Virol (2003) 1.01

Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J Virol (2000) 1.00

Impaired lymphoid chemokine-mediated migration due to a block on the chemokine receptor switch in human cytomegalovirus-infected dendritic cells. J Virol (2004) 1.00

Efficient human cytomegalovirus reactivation is maturation dependent in the Langerhans dendritic cell lineage and can be studied using a CD14+ experimental latency model. J Virol (2012) 0.99

Human cytomegalovirus-induced NKG2C(hi) CD57(hi) natural killer cells are effectors dependent on humoral antiviral immunity. J Virol (2013) 0.98

cGAS Senses Human Cytomegalovirus and Induces Type I Interferon Responses in Human Monocyte-Derived Cells. PLoS Pathog (2016) 0.95

Cytomegalovirus hijacks CX3CR1(hi) patrolling monocytes as immune-privileged vehicles for dissemination in mice. Cell Host Microbe (2014) 0.94

Murine cytomegalovirus abortively infects human dendritic cells, leading to expression and presentation of virally vectored genes. J Virol (2003) 0.92

Circulating dendritic cells isolated from healthy seropositive donors are sites of human cytomegalovirus reactivation in vivo. J Virol (2013) 0.91

Human cytomegalovirus paralyzes macrophage motility through down-regulation of chemokine receptors, reorganization of the cytoskeleton, and release of macrophage migration inhibitory factor. J Immunol (2009) 0.90

Human cytomegalovirus subverts the functions of monocytes, impairing chemokine-mediated migration and leukocyte recruitment. J Virol (2006) 0.90

Understanding MHC class I presentation of viral antigens by human dendritic cells as a basis for rational design of therapeutic vaccines. Front Immunol (2014) 0.89

Cytomegalovirus immune evasion by perturbation of endosomal trafficking. Cell Mol Immunol (2014) 0.89

Cross-presentation of human cytomegalovirus pp65 (UL83) to CD8+ T cells is regulated by virus-induced, soluble-mediator-dependent maturation of dendritic cells. J Virol (2002) 0.88

Charge cluster-to-alanine scanning of UL128 for fine tuning of the endothelial cell tropism of human cytomegalovirus. J Virol (2008) 0.88

Engineered dendritic cells from cord blood and adult blood accelerate effector T cell immune reconstitution against HCMV. Mol Ther Methods Clin Dev (2015) 0.88

Interplay between human cytomegalovirus and intrinsic/innate host responses: a complex bidirectional relationship. Mediators Inflamm (2012) 0.87

Human cytomegalovirus US2 causes similar effects on both major histocompatibility complex class I and II proteins in epithelial and glial cells. J Virol (2003) 0.86

The intimate relationship between human cytomegalovirus and the dendritic cell lineage. Front Microbiol (2014) 0.85

Cyclophilin A is required for efficient human cytomegalovirus DNA replication and reactivation. J Gen Virol (2012) 0.85

Mutational mapping of UL130 of human cytomegalovirus defines peptide motifs within the C-terminal third as essential for endothelial cell infection. J Virol (2010) 0.84

Dendritic cell biology in human cytomegalovirus infection and the clinical consequences for host immunity and pathology. Virulence (2012) 0.84

Human cytomegalovirus infection of langerhans-type dendritic cells does not require the presence of the gH/gL/UL128-131A complex and is blocked after nuclear deposition of viral genomes in immature cells. J Virol (2013) 0.83

Human cytomegalovirus impairs the function of plasmacytoid dendritic cells in lymphoid organs. PLoS One (2008) 0.83

Mutational mapping of pUL131A of human cytomegalovirus emphasizes its central role for endothelial cell tropism. J Virol (2011) 0.82

Human cytomegalovirus major immediate early 1 protein targets host chromosomes by docking to the acidic pocket on the nucleosome surface. J Virol (2013) 0.81

Human cytomegalovirus tropism for mucosal myeloid dendritic cells. Rev Med Virol (2014) 0.80

Modulation of dendritic cell functions by viral IL-10 encoded by human cytomegalovirus. Front Microbiol (2014) 0.79

RASCAL is a new human cytomegalovirus-encoded protein that localizes to the nuclear lamina and in cytoplasmic vesicles at late times postinfection. J Virol (2010) 0.79

Cytomegalovirus immune evasion of myeloid lineage cells. Med Microbiol Immunol (2015) 0.78

Tumor control in a model of bone marrow transplantation and acute liver-infiltrating B-cell lymphoma: an unpredicted novel function of cytomegalovirus. J Virol (2002) 0.77

Dendritic cells are susceptible to infection with wild-type adenovirus, inducing a differentiation arrest in precursor cells and inducing a strong T-cell stimulation. J Gen Virol (2009) 0.77

Subviral dense bodies of human cytomegalovirus stimulate maturation and activation of monocyte-derived immature dendritic cells. J Virol (2013) 0.76

HCMV Displays a Unique Transcriptome of Immunomodulatory Genes in Primary Monocyte-Derived Cell Types. PLoS One (2016) 0.76

Adenovirus E1A/E1B Transformed Amniotic Fluid Cells Support Human Cytomegalovirus Replication. Viruses (2016) 0.75

Herpesviral capture of immunomodulatory host genes. Virus Genes (2017) 0.75

A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell (1985) 16.46

Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol (1997) 5.86

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41

Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet (2001) 3.36

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia (2010) 3.31

Predominant immediate-early transcripts of human cytomegalovirus AD 169. J Virol (1984) 3.15

Quantification of fungal DNA by using fluorescence resonance energy transfer and the light cycler system. J Clin Microbiol (2000) 3.02

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia (2012) 2.78

Survival after bone marrow transplantation from cytomegalovirus seropositive sibling donors. Lancet (2001) 2.77

Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Lett (1997) 2.72

Fibroblasts, epithelial cells, endothelial cells and smooth muscle cells are major targets of human cytomegalovirus infection in lung and gastrointestinal tissues. J Gen Virol (1995) 2.66

Retracted Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med (2000) 2.64

Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood (1995) 2.43

Modification of human cytomegalovirus tropism through propagation in vitro is associated with changes in the viral genome. J Gen Virol (1999) 2.33

Human cytomegalovirus infections in nonimmunosuppressed critically ill patients. Crit Care Med (2001) 2.27

Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett (1997) 2.15

Comparison of different methods for extraction of DNA of fungal pathogens from cultures and blood. J Clin Microbiol (1997) 2.13

The two major structural phosphoproteins (pp65 and pp150) of human cytomegalovirus and their antigenic properties. J Gen Virol (1987) 2.13

Map position and nucleotide sequence of the gene for the large structural phosphoprotein of human cytomegalovirus. J Virol (1987) 2.11

The dominant phosphoprotein pp65 (UL83) of human cytomegalovirus is dispensable for growth in cell culture. J Virol (1995) 2.07

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant (2009) 2.00

Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood (2001) 1.93

Cytomegalovirus cell tropism. Curr Top Microbiol Immunol (2008) 1.89

Proteasome inhibitors: antitumor effects and beyond. Leukemia (2006) 1.87

Contaminations occurring in fungal PCR assays. J Clin Microbiol (1999) 1.86

Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet (1996) 1.85

Analysis of proteins encoded by IE regions 1 and 2 of human cytomegalovirus using monoclonal antibodies generated against recombinant antigens. Virology (1993) 1.83

Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant (2005) 1.79

Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant (2008) 1.78

Cell types involved in replication and distribution of human cytomegalovirus. Adv Virus Res (1996) 1.72

Human cytomegalovirus cell tropism and pathogenesis. Intervirology (1996) 1.71

Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70

Genomic localization, sequence analysis, and transcription of the putative human cytomegalovirus DNA polymerase gene. J Virol (1987) 1.67

The lower matrix protein pp65 is the principal viral antigen present in peripheral blood leukocytes during an active cytomegalovirus infection. J Gen Virol (1992) 1.67

Nuclear targeting of the tegument protein pp65 (UL83) of human cytomegalovirus: an unusual bipartite nuclear localization signal functions with other portions of the protein to mediate its efficient nuclear transport. J Virol (1995) 1.66

Molecular nature of two Haemophilus influenzae R factors containing resistances and the multiple integration of drug resistance transposons. J Bacteriol (1979) 1.66

Detection of PCR-amplified fungal DNA by using a PCR-ELISA system. Med Mycol (1998) 1.61

Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. J Infect Dis (1998) 1.58

Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation. J Infect Dis (1997) 1.57

Identification of the major capsid protein gene of human cytomegalovirus. J Virol (1989) 1.56

Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant (2008) 1.56

Tropism of human cytomegalovirus for endothelial cells is determined by a post-entry step dependent on efficient translocation to the nucleus. J Gen Virol (2000) 1.55

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant (2006) 1.53

Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis (2000) 1.47

Clinical-scale single-step CD4(+) and CD8(+) cell depletion for donor innate lymphocyte infusion (DILI). Bone Marrow Transplant (2007) 1.46

Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow Transplant (2009) 1.44

Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells. Blood (2001) 1.44

Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant (2009) 1.42

Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant (2004) 1.40

Prokaryotic expression of immunogenic polypeptides of the large phosphoprotein (pp150) of human cytomegalovirus. J Gen Virol (1988) 1.40

Molecular pathogenesis of Epstein-Barr virus associated posttransplant lymphomas: new insights through latent membrane protein 1 fingerprinting. Transplantation (2001) 1.39

Molecular characterization of a small Haemophilus influenzae plasmid specifying beta-lactamase and its relationship to R factors from Neisseria gonorrhoeae. J Gen Microbiol (1979) 1.38

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia (2009) 1.38

Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer (2010) 1.37

Transmission of cytomegalovirus to preterm infants through breast milk. Pediatr Infect Dis J (1998) 1.35

Structure of the transforming region of human cytomegalovirus AD169. J Virol (1984) 1.35

Tissue macrophages are infected by human cytomegalovirus in vivo. J Infect Dis (1996) 1.35

Continuous clearance of HIV in a vertically infected child. Lancet (1989) 1.35

Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis (2009) 1.35

Comparison between plasma and whole blood specimens for detection of Aspergillus DNA by PCR. J Clin Microbiol (2000) 1.33

Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood (2000) 1.30

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia (2009) 1.29

The G464S amino acid substitution in Candida albicans sterol 14alpha-demethylase causes fluconazole resistance in the clinic through reduced affinity. Biochem Biophys Res Commun (1999) 1.29

Early serodiagnosis of acute human cytomegalovirus infection by enzyme-linked immunosorbent assay using recombinant antigens. J Clin Microbiol (1994) 1.29

Screening for Aspergillus spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies. Br J Haematol (2001) 1.27

Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant (2000) 1.26

Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant (2005) 1.25

Large-scale screening of human sera with cytomegalovirus recombinant antigens. J Clin Microbiol (1990) 1.25

Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis. Rheumatol Int (1992) 1.25

Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2003) 1.24

Monoclonal antibody E-13 (M-810) to human cytomegalovirus recognizes an epitope encoded by exon 2 of the major immediate early gene. J Gen Virol (1992) 1.23

Diagnosis of invasive fungal infections in hematology and oncology--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol (2003) 1.21

Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia. Br J Haematol (2000) 1.20

Human cytomegalovirus as a direct pathogen: correlation of multiorgan involvement and cell distribution with clinical and pathological findings in a case of congenital inclusion disease. J Med Virol (2002) 1.20

Molecular properties of transmissible R factors of Haemophilus influenzae determing tetracycline resistance. J Gen Microbiol (1978) 1.19

Evaluation of plasmids in tetracycline resistant strains of Neisseria gonorrhoeae and Ureaplasma urealyticum in a case of severe urethritis. Eur J Epidemiol (1985) 1.18

Identification of medically important fungi by the Pyrosequencing technology. Mycoses (2004) 1.18

Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow Transplant (2008) 1.18

Detection of cytomegalovirus antibodies by an enzyme-linked immunosorbent assay using recombinant polypeptides of the large phosphorylated tegument protein pp150. J Clin Microbiol (1992) 1.18

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia (2011) 1.17

Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant (2009) 1.17

Efficient lytic infection of human arterial endothelial cells by human cytomegalovirus strains. J Virol (2000) 1.17